Endovascular therapies for malignant gliomas: Challenges and the future

12Citations
Citations of this article
51Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Malignant gliomas are very difficult tumors to treat, with few effective therapies, early progression and high rates of recurrence. Here we review the literature on malignant gliomas treated with endovascular therapy. Endovascular therapy for malignant gliomas falls into one of three categories: (1) neoadjuvant embolization and devascularization; (2) direct intra-arterial drug delivery; and (3) disruption of the blood-brain barrier for improved intra-arterial drug delivery. There is a range of therapeutic benefits based on the endovascular intervention used. Challenges remain for those who aim to treat malignant gliomas with an endovascular approach. Specifically, embolization is difficult to accomplish in the small vessels that feed into malignant gliomas, and intra-arterial chemotherapy has yet to prove itself better than traditional intravenous chemotherapy. However, there exists promise in the therapeutic potential of intra-arterial chemotherapy paired with disruption of the blood-brain barrier at tumor-specific sites, and as such, continued research to optimize this approach is expected to yield benefit for patients with malignant gliomas.

Cite

CITATION STYLE

APA

Su, Y. S., Ali, R., Feroze, A. H., Li, G., Lawton, M. T., & Choudhri, O. (2016, April 1). Endovascular therapies for malignant gliomas: Challenges and the future. Journal of Clinical Neuroscience. Churchill Livingstone. https://doi.org/10.1016/j.jocn.2015.10.019

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free